Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
MMWR Morb Mortal Wkly Rep ; 66(22): 579-583, 2017 Jun 09.
Artículo en Inglés | MEDLINE | ID: mdl-28594790

RESUMEN

Japanese encephalitis (JE) virus is the most important vaccine-preventable cause of encephalitis in the Asia-Pacific region. The World Health Organization (WHO) recommends integration of JE vaccination into national immunization schedules in all areas where the disease is a public health priority (1). This report updates a previous summary of JE surveillance and immunization programs in Asia and the Western Pacific in 2012 (2). Since 2012, funding for JE immunization has become available through the GAVI Alliance, three JE vaccines have been WHO-prequalified,* and an updated WHO JE vaccine position paper providing guidance on JE vaccines and vaccination strategies has been published (1). Data for this report were obtained from a survey of JE surveillance and immunization practices administered to health officials in countries with JE virus transmission risk, the 2015 WHO/United Nations Children's Fund Joint Reporting Form on Immunization, notes and reports from JE meetings held during 2014-2016, published literature, and websites. In 2016, 22 (92%) of 24 countries with JE virus transmission risk conducted JE surveillance, an increase from 18 (75%) countries in 2012, and 12 (50%) countries had a JE immunization program, compared with 11 (46%) countries in 2012. Strengthened JE surveillance, continued commitment, and adequate resources for JE vaccination should help maintain progress toward prevention and control of JE.


Asunto(s)
Encefalitis Japonesa/epidemiología , Encefalitis Japonesa/prevención & control , Vacunas contra la Encefalitis Japonesa/administración & dosificación , Vigilancia de la Población , Adolescente , Asia/epidemiología , Niño , Preescolar , Humanos , Programas de Inmunización , Esquemas de Inmunización , Lactante , Islas del Pacífico/epidemiología
2.
MMWR Morb Mortal Wkly Rep ; 63(39): 855-60, 2014 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-25275329

RESUMEN

Typhoid fever is a serious, systemic infection resulting in nearly 22 million cases and 216,500 deaths annually, primarily in Asia. Safe water, adequate sanitation, appropriate personal and food hygiene, and vaccination are the most effective strategies for prevention and control. In 2008, the World Health Organization (WHO) recommended use of available typhoid vaccines to control endemic disease and outbreaks and strengthening of typhoid surveillance to improve disease estimates and identify high-risk populations (e.g., persons without access to potable water and adequate sanitation). This report summarizes the status of typhoid surveillance and vaccination programs in the WHO South-East Asia (SEAR) and Western Pacific regions (WPR) during 2009-2013, after the revised WHO recommendations. Data were obtained from the WHO/United Nations Children's Fund (UNICEF) Joint Reporting Form on Immunization, a supplemental survey of surveillance and immunization program managers, and published literature. During 2009-2013, 23 (48%) of 48 countries and areas of SEAR (11) and WPR (37) collected surveillance or notifiable disease data on typhoid cases, with most surveillance activities established before 2008. Nine (19%) countries reported implementation of typhoid vaccination programs or recommended vaccine use during 2009-2013. Despite the high incidence, typhoid surveillance is weak in these two regions, and vaccination efforts have been limited. Further progress toward typhoid fever prevention and control in SEAR and WPR will require country commitment and international support for enhanced surveillance, targeted use of existing vaccines and availability of newer vaccines integrated within routine immunization programs, and integration of vaccination with safe water, sanitation, and hygiene measures.


Asunto(s)
Vigilancia de la Población , Fiebre Tifoidea/epidemiología , Fiebre Tifoidea/prevención & control , Vacunas Tifoides-Paratifoides/administración & dosificación , Asia Sudoriental/epidemiología , Niño , Preescolar , Humanos , Programas de Inmunización , Islas del Pacífico/epidemiología
3.
AIDS Behav ; 16(3): 618-25, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21274611

RESUMEN

We assessed prevalence of sexually transmitted infection (STIs), sexual risk behaviors, and factors associated with risk behaviors among HIV-infected MSM attending a public STI clinic serving MSM in Bangkok, Thailand. Between October 2005-October 2007, 154 HIV-infected MSM attending the clinic were interviewed about sexual risk behaviors and evaluated for STIs. Patients were examined for genital ulcers and had serologic testing for syphilis and PCR testing for chlamydia and gonorrhea. Results showed that sexual intercourse in the last 3 months was reported by 131 men. Of these, 32% reported anal sex without a condom. STIs were diagnosed in 41%. Factors associated with having sex without a condom were having a steady male partner, having a female partner and awareness of HIV status <1 month. Sexual risk behaviors and STIs were common among HIV-infected MSM in this study. This highlights the need for increased HIV prevention strategies for HIV-infected MSM.


Asunto(s)
Infecciones por VIH/epidemiología , Homosexualidad Masculina/estadística & datos numéricos , Asunción de Riesgos , Conducta Sexual/estadística & datos numéricos , Enfermedades Bacterianas de Transmisión Sexual/epidemiología , Adulto , Instituciones de Atención Ambulatoria , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Humanos , Masculino , Prevalencia , Parejas Sexuales , Enfermedades Bacterianas de Transmisión Sexual/diagnóstico , Enfermedades Bacterianas de Transmisión Sexual/prevención & control , Enfermedades Bacterianas de Transmisión Sexual/transmisión , Tailandia/epidemiología
4.
Int J Qual Health Care ; 24(4): 338-47, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22665387

RESUMEN

OBJECTIVE: We report experience of HIVQUAL-T implementation in Thailand. DESIGN: Program evaluation. SETTING: Twelve government hospital clinics. PARTICIPANTS: People living with HIV/AIDS (PLHAs) aged ≥15 years with two or more visits to the hospitals during 2002-08. INTERVENTION: HIVQUAL-T is a process for HIV care performance measurement (PM) and quality improvement (QI). The program includes PM using a sample of eligible cases and establishment of a locally led QI infrastructure and process. PM indicators are based on Thai national HIV care guidelines. QI projects address needs identified through PM; regional workshops facilitate peer learning. Annual benchmarking with repeat measurement is used to monitor progress. MAIN OUTCOME MEASURE: Percentages of eligible cases receiving various HIV services. RESULTS: Across 12 participating hospitals, HIV care caseloads were 4855 in 2002 and 13 887 in 2008. On average, 10-15% of cases were included in the PM sample. Percentages of eligible cases receiving CD4 testing in 2002 and 2008, respectively, were 24 and 99% (P< 0.001); for ARV treatment, 100 and 90% (P= 0.74); for Pneumocystis jiroveci pneumonia prophylaxis, 94 and 93% (P= 0.95); for Papanicolau smear, 0 and 67% (P< 0.001); for syphilis screening, 0 and 94% (P< 0.001); and for tuberculosis screening, 24 and 99% (P< 0.01). PM results contributed to local QI projects and national policy changes. CONCLUSIONS: Hospitals participating in HIVQUAL-T significantly increased their performance in several fundamental areas of HIV care linked to health outcomes for PLHA. This model of PM-QI has improved clinical care and implementation of HIV guidelines in hospital-based clinics in Thailand.


Asunto(s)
Infecciones por VIH/terapia , Servicio Ambulatorio en Hospital/organización & administración , Sector Público/organización & administración , Mejoramiento de la Calidad/organización & administración , Infecciones Oportunistas Relacionadas con el SIDA/prevención & control , Síndrome de Inmunodeficiencia Adquirida/terapia , Antirretrovirales/administración & dosificación , Benchmarking , Recuento de Linfocito CD4 , Humanos , Sistemas de Información/organización & administración , Servicio Ambulatorio en Hospital/normas , Proyectos Piloto , Evaluación de Programas y Proyectos de Salud , Mejoramiento de la Calidad/normas , Indicadores de Calidad de la Atención de Salud/organización & administración , Autocuidado/métodos , Tailandia
5.
J Urban Health ; 88(3): 533-44, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21336505

RESUMEN

The aim of this study is to estimate HIV prevalence and assess sexual behaviors in a high-risk and difficult-to-reach population of clients of female sex workers (FSWs). A modified variation of respondent-driven sampling was conducted among FSWs in Bangkok, where FSWs recruited 3 FSW peers, 1 client, and 1 nonpaying partner. After informed consent was obtained, participants completed a questionnaire, were HIV-tested, and were asked to return for results. Analyses were weighted to control for the design of the survey. Among 540 FSWs, 188 (35%) recruited 1 client, and 88 (16%) recruited 1 nonpaying partner. Clients' median age was 38 years. HIV prevalence was 20% and was associated with younger age at first sexual experience [relative risk (RR) = 3.10, 95% confidence interval (CI) 1.16-8.24] and condom use during last sexual encounter with regular partner (RR = 3.97, 95% CI 1.09-14.61). Median age of nonpaying partners was 34 years, and HIV prevalence was 15.1%. There were 56 discordant FSW-client pairs and 14 discordant FSW-nonpaying partner pairs. Condom use was relatively high among discordant FSW-client pairs (90.1%) compared to discordant FSW-nonpaying partner pairs (18.7%). Results suggest that sexual partners of FSWs have a high HIV prevalence and can be a bridge for HIV transmission to other populations. Findings also highlight the importance of initiating surveillance and targeted programs for FSW partners, and demonstrate a recruitment method for hard-to-reach populations.


Asunto(s)
Condones/estadística & datos numéricos , Infecciones por VIH/prevención & control , Conducta de Reducción del Riesgo , Trabajo Sexual/estadística & datos numéricos , Serodiagnóstico del SIDA/estadística & datos numéricos , Adulto , Computadoras de Mano , Condones/economía , Condones/provisión & distribución , Femenino , Infecciones por VIH/epidemiología , Infecciones por VIH/transmisión , Humanos , Entrevistas como Asunto , Masculino , Conducta Sexual/estadística & datos numéricos , Parejas Sexuales , Encuestas y Cuestionarios , Tailandia/epidemiología , Adulto Joven
6.
Lancet Reg Health West Pac ; 6: 100053, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34327400

RESUMEN

BACKGROUND: In 2012, Fiji became the first independent Pacific island country to introduce rotavirus vaccine. We describe the impact of rotavirus vaccine on all-cause diarrhoea admissions in all ages, and rotavirus diarrhoea in children <5 years of age. METHODS: An observational study was conducted retrospectively on all admissions to the public tertiary hospitals in Fiji (2007-2018) and prospectively on all rotavirus-positive diarrhoea admissions in children <5 years at two hospital sites (2006-2018, and 2010-2015), along with rotavirus diarrhoea outpatient presentations at one secondary public hospital (2010-2015). The impact of rotavirus vaccine was determined using incidence rate ratios (IRR) of all-cause diarrhoea admissions and rotavirus diarrhoea, comparing the pre-vaccine and post-vaccine periods. All-cause admissions were used as a control. Multiple imputation was used to impute missing stool samples. FINDINGS: All-cause diarrhoea admissions declined among all age groups except among infants ≤2 months old and adults ≥55 years. For children <5 years, all-cause diarrhoea admissions declined by 39% (IRR)=0•61, 95%CI; 0•57-0•65, p-value<0•001). There was an 81% (95%CI; 51-94%) reduction in mortality among all-cause diarrhoea admissions in children under <5 years. Rotavirus diarrhoea admissions at the largest hospital among children <5 years declined by 87% (IRR=0•13, 95%CI; 0•10-0•17, p-value<0•001). Among rotavirus diarrhoea outpatient presentations, the IRR was 0•39 (95%CI; 0•11, 1.21, p-value=0.077). INTERPRETATIONS: Morbidity and mortality due to rotavirus and all-cause diarrhoea in Fiji has declined in people aged 2 months to 54 years after the introduction of the RV vaccine. FUNDING: Supported by WHO and the Australian Government.

7.
Jt Comm J Qual Patient Saf ; 36(12): 541-51, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21222356

RESUMEN

BACKGROUND: As increasing numbers of children initiate antiretroviral treatment (ART), a systematic process is needed to measure and improve pediatric HIV care quality. METHODS: Pediatric HIVQUAL-T, a model for performance measurement and quality improvement (QI), was adapted from the U.S. HIVQUAL model by incorporating Thai national guidelines as standards. In each of five pilot-site hospitals in Thailand in 2005-2007, clinical data abstracted from patient records were used to identify priority areas for QI. Improvement strategies were designed by clinic teams in different care system areas, and indicators were remeasured in 2006 and 2007. RESULTS: At the five hospitals, 1119 HIV-infected children younger than 15 years of age received care in 2005, 1183 in 2006, and 1,341 in 2007--of whom 460, 435, and 418, respectively, were selected for chart abstraction. Of the eligible children, > or = 95% received clinical monitoring, annual CD4 count monitoring, ART, and adherence and growth assessments; 60%-90% received Pneumocystis jiroveci pneumonia (PCP) prophylaxis, tuberculosis (TB) screening, oral health assessments, and HIV disclosure. Indicators with a score < or = 40% in 2005 but with significant improvement (p < .05) in 2006-2007 following QI activities were Mycobacterium avium complex (MAC) prophylaxis, and cytomegalovirus (CMV) retinitis and immunization screenings. CONCLUSIONS: Despite the promulgation of national guidelines, performance rates of some pediatric HIV indicators needed improvement. The pediatric HIVQUAL-T model facilitates use of hospital data for pediatric HIV care improvement and indicates that the U.S. HIVQUAL model is adaptable to developing countries.


Asunto(s)
Infecciones por VIH/terapia , Administración Hospitalaria , Calidad de la Atención de Salud/organización & administración , Adolescente , Antirretrovirales/uso terapéutico , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Sistemas de Información/organización & administración , Evaluación de Procesos, Atención de Salud/organización & administración , Indicadores de Calidad de la Atención de Salud/organización & administración , Tailandia
8.
Vaccine ; 37(2): 296-305, 2019 01 07.
Artículo en Inglés | MEDLINE | ID: mdl-30502068

RESUMEN

Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of PCVs in lower income settings, particularly in Asia. In 2013, the Lao People's Democratic Republic (Lao PDR) introduced 13-valent PCV (PCV13) as a 3 + 0 schedule (doses at 6, 10 and 14 weeks of age) with limited catch-up vaccination. We conducted two cross-sectional carriage surveys (pre- and two years post-PCV) to assess the impact of PCV13 on nasopharyngeal pneumococcal carriage in 5-8 week old infants (n = 1000) and 12-23 month old children (n = 1010). Pneumococci were detected by quantitative real-time PCR, and molecular serotyping was performed using DNA microarray. Post PCV13, there was a 23% relative reduction in PCV13-type carriage in children aged 12-23 months (adjusted prevalence ratio [aPR] 0.77 [0.61-0.96]), and no significant change in non-PCV13 serotype carriage (aPR 1.11 [0.89-1.38]). In infants too young to be vaccinated, there was no significant change in carriage of PCV13 serotypes (aPR 0.74 [0.43-1.27]) or non-PCV13 serotypes (aPR 1.29 [0.85-1.96]), although trends were suggestive of indirect effects. Over 70% of pneumococcal-positive samples contained at least one antimicrobial resistance gene, which were more common in PCV13 serotypes (p < 0.001). In 12-23 month old children, pneumococcal density of both PCV13 serotypes and non-PCV13 serotypes was higher in PCV13-vaccinated compared with undervaccinated children (p = 0.004 and p < 0.001, respectively). This study provides evidence of PCV13 impact on carriage in a population without prior PCV7 utilisation, and provides important data from a lower-middle income setting in Asia. The reductions in PCV13 serotype carriage in vaccine-eligible children are likely to result in reductions in pneumococcal transmission and disease in Lao PDR.


Asunto(s)
Portador Sano/epidemiología , Infecciones Neumocócicas/epidemiología , Vacunas Neumococicas/administración & dosificación , Streptococcus pneumoniae/aislamiento & purificación , Portador Sano/inmunología , Estudios Transversales , Femenino , Humanos , Inmunidad Colectiva , Lactante , Laos/epidemiología , Masculino , Nasofaringe/microbiología , Infecciones Neumocócicas/prevención & control , Reacción en Cadena de la Polimerasa , Prevalencia , Serogrupo , Serotipificación , Vacunación , Vacunas Conjugadas/administración & dosificación
9.
Vaccine ; 36(48): 7399-7407, 2018 11 19.
Artículo en Inglés | MEDLINE | ID: mdl-30431003

RESUMEN

BACKGROUND: The introduction of inactivated poliovirus vaccine (IPV) to the Philippines' national immunization schedule meant the addition of a third injectable vaccine at a child's 14-week immunization visit. Although previous studies have shown that providing multiple vaccines at the same time affected neither the risk of severe adverse events nor vaccine efficacy, concerns were raised that providing three injections at a single visit, with two injections in one leg, might be unacceptable to health care providers (HCP) and infant caregivers. METHODS: We conducted pre- and post-IPV introduction surveys on the acceptance and acceptability of the additional injectable vaccine in three of the Philippines' 17 administrative regions. Regions 3 and 6 were included in the pre-introduction phase and Regions 3, 6 and 10 were included in the post-introduction phase. Thirty public health centers (PHCs) were randomly sampled from each region. HCPs and infant caregivers were interviewed. In addition, vaccination records from a minimum of 20 eligible children pre-introduction and 10 children post-introduction per PHC were reviewed. RESULTS AND DISCUSSION: We interviewed 89 HCPs and 286 infant caregivers during the pre-introduction phase and 137 HCPs and 455 caregivers during the post-introduction phase. Among 986 vaccination records reviewed post-introduction, 84% (n = 826) of children received all three recommended injections at one visit, with a range from 61% (209/342) in Region 10 to 100% (328/328) in Region 3. The proportion of HCPs reporting that they had administered three or more injectable vaccines and the proportion of caregivers that would be comfortable with their child receiving three or more injectable vaccines at one visit increased from pre- to post-introduction (p < 0.0001 for both). Eighty-seven percent of HCPs that had administered three or more injectable vaccines post-introduction reported being comfortable or very comfortable with the number of vaccines they had administered.


Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Personal de Salud/psicología , Esquemas de Inmunización , Poliomielitis/prevención & control , Vacuna Antipolio de Virus Inactivados/administración & dosificación , Vacunación/psicología , Adulto , Femenino , Humanos , Lactante , Inyecciones/efectos adversos , Inyecciones/psicología , Masculino , Persona de Mediana Edad , Filipinas/epidemiología , Poliomielitis/epidemiología , Encuestas y Cuestionarios , Vacunación/estadística & datos numéricos
10.
PLoS Negl Trop Dis ; 9(3): e0003630, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25794009

RESUMEN

BACKGROUND: Japanese encephalitis virus (JEV) is an important cause of encephalitis in most of Asia, with high case fatality rates and often significant neurologic sequelae among survivors. The epidemiology of JE in the Philippines is not well defined. To support consideration of JE vaccine for introduction into the national schedule in the Philippines, we conducted a systematic literature review and summarized JE surveillance data from 2011 to 2014. METHODS: We conducted searches on Japanese encephalitis and the Philippines in four databases and one library. Data from acute encephalitis syndrome (AES) and JE surveillance and from the national reference laboratory from January 2011 to March 2014 were tabulated and mapped. RESULTS: We identified 29 published reports and presentations on JE in the Philippines, including 5 serologic surveys, 18 reports of clinical cases, and 8 animal studies (including two with both clinical cases and animal data). The 18 clinical studies reported 257 cases of laboratory-confirmed JE from 1972 to 2013. JE virus (JEV) was the causative agent in 7% to 18% of cases of clinical meningitis and encephalitis combined, and 16% to 40% of clinical encephalitis cases. JE predominantly affected children under 15 years of age and 6% to 7% of cases resulted in death. Surveillance data from January 2011 to March 2014 identified 73 (15%) laboratory-confirmed JE cases out of 497 cases tested. SUMMARY: This comprehensive review demonstrates the endemicity and extensive geographic range of JE in the Philippines, and supports the use of JE vaccine in the country. Continued and improved surveillance with laboratory confirmation is needed to systematically quantify the burden of JE, to provide information that can guide prioritization of high risk areas in the country and determination of appropriate age and schedule of vaccine introduction, and to measure the impact of preventive measures including immunization against this important public health threat.


Asunto(s)
Encefalitis Japonesa/epidemiología , Vacunas contra la Encefalitis Japonesa/administración & dosificación , Adolescente , Anticuerpos Antivirales/sangre , Niño , Preescolar , Virus de la Encefalitis Japonesa (Especie)/inmunología , Femenino , Humanos , Lactante , Vacunas contra la Encefalitis Japonesa/inmunología , Masculino , Filipinas/epidemiología , Salud Pública , Estudios Seroepidemiológicos , Vacunación
11.
BMC Public Health ; 4: 21, 2004 Jun 09.
Artículo en Inglés | MEDLINE | ID: mdl-15189565

RESUMEN

BACKGROUND: Sexually transmitted diseases (STDs) are a major public health problem among young people and can lead to the spread of HIV. Previous studies have primarily addressed barriers to STD care for symptomatic patients. The purpose of our study was to identify perceptions about existing barriers to and ideal services for STDs, especially asymptomatic screening, among young people in a southeastern community. METHODS: Eight focus group discussions including 53 White, African American, and Latino youth (age 14-24) were conducted. RESULTS: Perceived barriers to care included lack of knowledge of STDs and available services, cost, shame associated with seeking services, long clinic waiting times, discrimination, and urethral specimen collection methods. Perceived features of ideal STD services included locations close to familiar places, extended hours, and urine-based screening. Television was perceived as the most effective route of disseminating STD information. CONCLUSIONS: Further research is warranted to evaluate improving convenience, efficiency, and privacy of existing services; adding urine-based screening and new services closer to neighborhoods; and using mass media to disseminate STD information as strategies to increase STD screening.


Asunto(s)
Negro o Afroamericano/psicología , Hispánicos o Latinos/psicología , Tamizaje Masivo/estadística & datos numéricos , Aceptación de la Atención de Salud/etnología , Enfermedades de Transmisión Sexual/diagnóstico , Población Blanca/psicología , Adolescente , Servicios de Salud del Adolescente/normas , Adulto , Femenino , Grupos Focales , Conocimientos, Actitudes y Práctica en Salud , Accesibilidad a los Servicios de Salud/normas , Humanos , Masculino , Tamizaje Masivo/psicología , North Carolina/epidemiología , Aceptación de la Atención de Salud/psicología , Educación del Paciente como Asunto , Prejuicio , Enfermedades de Transmisión Sexual/etnología , Enfermedades de Transmisión Sexual/prevención & control , Percepción Social
12.
Postgrad Med ; 98(3): 87-104, 1995 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29231096

RESUMEN

Preview A variety of genital pathogens, many of which are sexually transmitted, cause infections of the vagina and cervix. Discharge is often a prominent and telling symptom. Which infectious agents should be suspected when the discharge is accompanied by itching? Vulvar pain? Odor? Which laboratory tests are most helpful in making a diagnosis? The authors answer these and other questions in this overview of genital infections in women.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA